Unit Trust (UCITS compliant)

Legal & General Global Health & Pharmaceuticals Index Trust

Open or transfer a stocks and shares ISA

Apply now

Important customer notice:

The extreme market uncertainty caused by COVID-19 meant that trading in the L&G UK Property Fund was suspended from 18th March 2020. We intend that the fund will reopen on 13th October 2020. Find out more

Fund facts

Fund size
£625.7m
Base currency
GBP
Launch date
1 Nov 2000
Domicile
UK
Share class launch

Statistics

Historical yield
0.9%

As at 31 Aug 2020

Fund aim

The objective of the Fund is to provide growth by tracking the capital performance of the FTSE World Index - Health Care, the “Index”. This objective is after the deduction of charges and taxation.

Benchmark

FTSE World - Health Care Index

  • What does it invest in? Invests in the shares of global companies engaged in healthcare, pharmaceutical and biotechnology activities, as represented by the Index.
  • How does it invest? Passively managed, aiming to replicate the performance of the Index.

Further details

Costs

Price basis
Dual
Initial charge
0.00%
Ongoing charges figure
0.69%
Bid / Offer spread
0.19%

Codes

ISIN
GB0001955532
SEDOL
0195553
Bloomberg
LEGGHPA
MEX
LGHPIA

Dealing information

Valuation frequencyDaily, 3pm (UK time)
Dealing frequencyDaily
Settlement periodT+4

Performance

Source: Lipper

Performance (%)
Select period:
Change

    Performance summary (%)

    As at 31 Aug 2020

    CumulativeFundBenchmark
    1 month0.340.12
    6 months13.9411.85
    Year to date6.226.67
    3 years32.6035.73
    5 years68.6281.59
    Since launch253.08-
    AnnualisedFundBenchmark
    1 year11.0811.61
    3 years9.8510.71
    5 years11.0012.66
    Since launch6.56-

    As at 30 Jun 2020

    CumulativeFundBenchmark
    Quarterly14.4615.02
    Year to date7.278.90
    3 years35.3941.73
    5 years71.0983.89
    Since launch256.56-
    AnnualisedFundBenchmark
    1 year16.0417.80
    3 years10.6212.32
    5 years11.3312.94
    Since launch6.68-
    Rolling 12-month performance
    Calendar year performance
    Monthly performance
    Annualised performance

    Rolling 12-month performance to last quarter end (%)

    12 months to 30 June 2016 2017 2018 2019 2020
    Fund11.1313.713.8912.2716.08
    Benchmark14.6413.185.0614.4717.86

    Calendar year performance (%)

    2015 2016 2017 2018 2019
    Fund11.3111.359.216.8518.38
    Benchmark13.8312.5210.799.8718.19

    Monthly performance (%)

    Annualised performance (%)

    1 year3 years5 yearsSince launch
    Fund11.089.8511.006.56
    Benchmark11.6110.7112.66-

    Annualised performance (%)

    1 year3 years5 yearsSince launch
    Fund16.0410.6211.336.68
    Benchmark17.8012.3212.94-

    Performance for the C Acc unit class in GBP, launched on 22 February 2019. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the C Inc unit class in GBP, launched on 22 February 2019. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the F Acc unit class in GBP, launched on 20 December 2012. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the F Inc unit class in GBP, launched on 20 December 2012. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the I Acc unit class in GBP, launched on 26 August 2005. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the I Inc unit class in GBP, launched on 26 August 2005. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the R Acc unit class in GBP, launched on 01 November 2000. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the R Inc unit class in GBP, launched on 01 November 2000. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Portfolio

    As at 31 Aug 2020. All data source LGIM unless otherwise stated. Totals may not sum due to rounding. In order to minimise transaction costs, the Fund will not always own all the assets that constitute the index and on occasion it will own assets that are not in the index.

    Sector (%)

    Health Care100.0

    Market capitalisation (%)

    Large87.9
    Mid12.1
    Top 10 holdings37.6
    Rest of portfolio62.4
    No. of holdings in fund176
    No. of holdings in index176

    Top 10 holdings (%)

    Johnson & Johnson6.8
    Unitedhealth Group Inc5.0
    Roche4.1
    Merck & Co. Inc.3.6
    Pfizer Inc3.6
    Abbott Laboratories3.3
    Novartis3.1
    Abbvie Inc2.8
    Thermo Fisher Scientific2.8
    Amgen Inc2.5

    Country (%)

    United States64.1
    Switzerland9.1
    Japan7.3
    United Kingdom4.6
    Denmark3.2
    France3.1
    Germany2.3
    Australia2.2
    Netherlands0.9
    Other3.2

    Management Team

    The Index Fund Management team comprises 25 fund managers, supported by two analysts. Management oversight is provided by the Global Head of Index Funds. The team has average industry experience of 15 years, of which seven years has been at LGIM, and is focused on achieving the equally important objectives of close tracking and maximising returns.

    LGIMIndex Fund Management Team

    Literature

    Income

    Latest dividends

    The latest dividends are shown below. The historic level of income generated by this fund may go down as well up and will vary over time.

    of

    Dividend history

    Total dividends paid in each financial year of the fund.

    Prices

    Name
    C GBP Acc
    Bid price
    60.11p
    Offer price
    60.21p
    Absolute change
    -0.0098
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    C GBP Inc
    Bid price
    59.28p
    Offer price
    59.39p
    Absolute change
    -0.0096
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    F GBP Acc
    Bid price
    92.31p
    Offer price
    92.48p
    Absolute change
    -0.015
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    F GBP Inc
    Bid price
    77.26p
    Offer price
    77.40p
    Absolute change
    -0.0126
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    I GBP Acc
    Bid price
    98.18p
    Offer price
    98.36p
    Absolute change
    -0.016
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    I GBP Inc
    Bid price
    77.25p
    Offer price
    77.39p
    Absolute change
    -0.0126
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    R GBP Acc
    Bid price
    88.35p
    Offer price
    88.51p
    Absolute change
    -0.0144
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    R GBP Inc
    Bid price
    76.91p
    Offer price
    77.05p
    Absolute change
    -0.0125
    Currency
    GBP
    Price time
    15:00 UK time

    Key risks

    The value of an investment and any income taken from it is not guaranteed and can go down as well as up, you may not get back the amount you originally invested.

    Past performance is no guarantee of future results.

    The return from this fund is dependent on relatively few individual investments. This means that a fall in the value of an individual investment can have a major impact on the overall performance of the fund.

    Most of the fund holds investments from a particular market sector, that of health, pharmaceuticals and biotechnology. Funds like this can be more volatile than funds that invest across many market sectors. This is because the value of the fund can go up and down more often and by larger amounts than funds that are spread more widely, especially in the short term.

    The fund could lose money if any institution providing services such as acting as counterparty to derivatives or other instruments, becomes unwilling or unable to meet its obligations to the fund.

    Derivatives are highly sensitive to changes in the value of the asset on which they are based and can increase the size of losses and gains.

    The fund may have underlying investments that are valued in currencies that are different from sterling (British pounds). Exchange rate fluctuations will impact the value of your investment. Currency hedging techniques may be applied to reduce this impact but may not entirely eliminate it.

    Index disclaimer

    Source: London Stock Exchange Group plc and its group undertakings (collectively, the “LSE Group”). © LSE Group 2020. FTSE Russell is a trading name of certain of the LSE Group companies. “FTSE®” is a trade mark of the relevant LSE Group companies and is used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company’s express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication.

    Start investing today

    Our range of funds has all the options to help you achieve your goals

    Get started

    Compare funds

    Compare features and performance of all Legal & General funds

    Find out more

    Learn the basics

    The investment world can seem complicated, but it doesn’t have to be

    Find out more